Kymab Presents Poster Detailing Adaptive Phase 1/2 Clinical Trial for its KY1044 Anti-ICOS Program at ASCO 2019 Annual Meeting
June 01, 2019 07:00 ET
|
Kymab Group Ltd
Kymab Presents Poster Detailing Adaptive Phase 1/2 Clinical Trial for its KY1044 Anti-ICOS Program at ASCO 2019 Annual Meeting Clinical trial initiated in February 2019 in the U.S., MD Anderson...
Kymab Appoints Pharmaceutical Veteran Simon Sturge as Chief Executive Officer
April 08, 2019 07:00 ET
|
Kymab Group Ltd
Kymab Appoints Pharmaceutical Veteran Simon Sturge as Chief Executive Officer Cambridge, UK; April 8, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics,...
Kymab Announces Promising Results from Initial Clinical Study of New Antibody KY1005 for Treatment of Autoimmune Diseases
July 30, 2018 04:00 ET
|
Kymab Group Ltd
Kymab Announces Promising Results from Initial Clinical Study of New Antibody KY1005 for Treatment of Autoimmune Diseases Top-line Phase I data demonstrated favorable safety, pharmacokinetics and...
Kymab Announces Agreement to Evaluate KY1044, its Novel Antibody Targeting ICOS, and Anti-PD-L1 Immunotherapy for testing in Multiple Solid Tumors
June 28, 2018 07:04 ET
|
Kymab Group Ltd
Kymab Announces Agreement to Evaluate KY1044, its Novel Antibody Targeting ICOS, and Anti-PD-L1 Immunotherapy for testing in Multiple Solid Tumors Phase I/II studies will evaluate Kymab’s lead...
Kymab to present data on its lead immuno-oncology antibody, demonstrating strong potential for inhibiting tumour growth
November 08, 2017 04:01 ET
|
Kymab Group Ltd
Kymab to present data on its lead immuno-oncology antibody, demonstrating strong potential for inhibiting tumour growth Cambridge, UK, 8 November 2017: Kymab Group Limited ("Kymab"), a...
Kymab and Seattle Children's Research Institute publish impressive results using Kymab's KY1005 in a model of Acute Graft versus Host Disease (aGVHD) in Science Translational Medicine
September 21, 2017 04:00 ET
|
Kymab Group Ltd
Kymab and Seattle Children's Research Institute publish impressive results using Kymab's KY1005 in a model of Acute Graft versus Host Disease (aGVHD) in Science Translational Medicine KY1005 in...
Kymab Announces Clinical Update on its promising new antibody KY1005 for treatment of autoimmune diseases
July 31, 2017 04:20 ET
|
Kymab Group Ltd
Kymab Announces Clinical Update on its promising new antibody KY1005 for treatment of autoimmune diseases The third dosing cohort has been completed and 24 patients have now been dosed. ...
Kymab Group Ltd: Kymab appoints Dr Martin Nicklasson as Non-Executive Chair
June 16, 2017 04:01 ET
|
Kymab Group Ltd
Kymab appoints Dr Martin Nicklasson as Non-Executive Chair Cambridge, UK, 16 June 2017 - Kymab Group Limited ("Kymab"), a leading human monoclonal antibody biopharmaceutical group, announces the...